Stool test duo could revolutionize cancer surveillance in colitis

NCT ID NCT07742410

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study tests whether combining two stool tests—fecal immunochemical test (FIT) and fecal calprotectin (FC)—can accurately detect precancerous or cancerous changes in people with long-standing ulcerative colitis. Participants will provide stool samples and then undergo a special colonoscopy (linked color imaging) to confirm findings. The goal is to see if this non-invasive approach can effectively guide surveillance and potentially reduce the need for frequent invasive procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fecal immunochemical test (FIT) and fecal calprotectin (FC) stool tests, followed by linked color imaging (LCI) colonoscopy
What this could lead to
If effective, this stool test combo could become a routine pre-screening step, helping catch precancerous changes earlier and reducing the need for frequent colonoscopies in ulcerative colitis patients.
What could go wrong
The trial is observational and relatively small, so results may not apply broadly. Stool tests may miss some early cancers, and the added testing could increase anxiety or costs without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.